Bristol Myers Squibb Reports Q2 2026 Results — Conference Call at 8:15 AM ET
BMY sits 51% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb released its Q2 2026 financial results this morning, with a conference call scheduled for 8:15 a.m. ET. The press release and investor presentation are available on the company's website, but no specific numbers were disclosed in the headline or article body. This follows a Q1 marked by generic erosion and IRA pricing pressure, and a series of positive pipeline developments including mezigdomide's FDA acceptance and Opdivo's EU label expansion. The market will focus on whether Q2 revenue and EPS trends improved, and any updates on the Hengrui collaboration or upcoming Milvexian data readouts. The stock is trading near its 52-week high, raising the bar for a positive surprise.
At the time of this announcement, BMY was trading at $64.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $128.9B. The 52-week trading range was $42.52 to $64.97. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.